<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393715</url>
  </required_header>
  <id_info>
    <org_study_id>CNO20162</org_study_id>
    <nct_id>NCT03393715</nct_id>
  </id_info>
  <brief_title>Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes</brief_title>
  <acronym>CHRONIC1</acronym>
  <official_title>Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yaounde Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Yaounde 1</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yaounde Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We assessed the influence of time of administration of ACE inhibitors on circadian blood
      pressure control in sub Saharan type 2 diabetes patients with stage 1 hypertension over 56
      days as first line treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Renin-angiotensin system antagonists represent the mainstay of blood pressure
      (BP) lowering treatment options in people with diabetes. ACE inhibitors have a long half-life
      and offer the advantage of a single daily dose, usually empirically taken in the morning.

      Objective: We assessed the influence of time of administration of ACE inhibitors on circadian
      BP control in type 2 diabetes (T2D) patients with stage 1 hypertension.

      Methods: Twenty T2D patients (9 being women) with a mean age of 58.7 years, diagnosed with
      stage 1 of hypertension and naive to BP lowering medications, were included. They were
      randomly allocated to receive perindopril 10 mg/day as a monotherapy either in the morning or
      in the evening for 28 days, with crossover without washout period on day 29th and additional
      28 days follow-up. A 24-hour ambulatory BP monitoring (ABPM) was performed at baseline, days
      28 and 56.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>open label randomised controlled trial with crossover of perindopril administered in the morning versus evening on blood pressure control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour blood pressure profile</measure>
    <time_frame>56 days</time_frame>
    <description>Overall blood pressure control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Night time blood pressure dip</measure>
    <time_frame>56 days</time_frame>
    <description>Blood pressure drop at night</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Perindopril morning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg of perindopril oral tablet once daily in the morning for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perindopril evening</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg of perindopril oral tablet once daily in the evening for 56 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril Oral Tablet</intervention_name>
    <description>Perindopril oral tablet morning versus evening</description>
    <arm_group_label>Perindopril morning</arm_group_label>
    <arm_group_label>Perindopril evening</arm_group_label>
    <other_name>Coversyl 10 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Grade 1 hypertension

          -  Informed consent

        Exclusion Criteria:

          -  estimated creatinine clearance≤ 60ml/min

          -  White coat hypertension after initial 24 hour ABPM

          -  Previous antihypertensive treatment

          -  Pregnant women

          -  Individuals working during the night

          -  Hyperkalemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugène Sobngwi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yaounde Central Hospital</affiliation>
  </overall_official>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yaounde Central Hospital</investigator_affiliation>
    <investigator_full_name>Sobngwi Eugene</investigator_full_name>
    <investigator_title>Professor of Endocrinology and Diabetes</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Perindopril</keyword>
  <keyword>chronobiology</keyword>
  <keyword>Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

